CLAIMS

1. A compound of Formula (**I**):



(**I**)

or a pharmaceutically acceptable salt thereof;

wherein:

A is selected from the group:



(A-1) , (A-2) , (A-3) , (A-4) , and (A-5) ;

R^1 is C_1-C_6 haloalkyl or C_1-C_6 alkyl;

R^2 and R^3 is independently selected from H, halo, C_1-C_6 alkyl or alkoxy;

R^4 is halo, cyano, nitro, $-S(O)_xR^a$, $-NR^bR^c$, C_1-C_6 alkyl, C_1-C_6 alkoxy, $-C(O)R^a$, $-C(O)OR^a$, or $-C(O)NR^bR^c$;

R^a is H, aryl, heteroaryl, or C_1-C_6 alkyl;

each R^b and R^c is independently H, $-S(O)_xR^a$, $-C(O)R^a$, C_1-C_6 alkyl, or C_1-C_6 alkoxy, or R^b and R^c taken together with the atom to which they are attached form a ring;

n is an integer from 0 to 2; and

x is an integer from 0 to 2;

wherein when A is (A-1) or (A-2), then R^1 is selected from: $-CHF_2$, $-CH_2F$, $-CCl_3$, $-CHCl_2$, $-CH_2Cl$, - CBr_3, $-CHBr_2$, $-CH_2Br$, or C_1-C_6 alkyl; or

when A is (A-3) or (A-5), R^1 is $–CH_3$, $-CH_2F$, $-CH_2OCH_3$, or $–CHF_2$, and *n* is 0, then at least one of R^2 and R^3 is not H.

2. The compound of claim 1, wherein *n* is 0 or 1.

3. The compound of claim 1, wherein *n* is 0.

4. The compound of claim 1, wherein *n* is 1.

5. The compound of claim 1, wherein the compound of the Formula (**I**) is selected from a compound of Formula (**Ia**):



(**Ia**).

6. The compound of claim 1, wherein the compound of the Formula (**I**) is selected from a compound of the Formula (**Ib**):



(**Ib**).

7. The compound of claim 1, wherein the compound of the Formula (**I**) is selected from a compound of the Formula (**II**):



(**II**).

8. The compound of claim 1, wherein R^1 is C_1-C_6 alkyl.

9. The compound of claim 1, wherein R^1 is -CH_3.

10. The compound of claim 1, wherein R^2 and R^3 are H.

11. The compound of claim 1, wherein *n* is 1 and R^4 is halo, cyano, -$S(O)_xR^a$, or C_1-C_6 alkyl.

12. The compound of claim 11, wherein R^4 is -CH_3.

13. The compound of claim 1, wherein R^4 is -$C(O)OR^a$.

14. The compound of claim 1, wherein R^4 is -$C(O)NR^bR^c$.

15. The compound of claim 13, wherein R^a is H or C_1-C_6 alkyl (e.g., –CH_2CH_3).

16. The compound of claim 14, wherein R^b and R^c are H.

17. The compound of claim 1, wherein R^4 is cyano.

18. The compound of claim 11, wherein R^4 is -$S(O)_2CH_3$.

19. The compound of claim 1, wherein A is selected from the group:



, , and .

20. The compound of claim 1, wherein the compound is selected from the group



SA-1

,



SA-2

,



SA-3

,



SA-4

,



SA-5

,



SA-6

,



SA-7

,



SA-8

,



SA-9



SF-1,



SF-2,



SF-3,



SF-4,



SG-1,



SG-3,



SG-4,



SG-5,



SE-1,



SE-2,



SE-3,



SE-4,



SE-5 ,



SE-6 ,



SM-1 ,



SM-3 ,



SM-4 ,



SM-5 ,



SO-1 ,



SO-2 ,



SL-1



SL-2



SH-1



SH-2



SB-1



SB-2



SB-4



SB-5



SB-6



SD-1,



SD-2,



SD-3,



SD-4,



SP-1,



SP-2,



SP-3,



SP-4,



SP-5,



SI-1,



SI-2,



SI-3,



SI-4 ,



SQ-1 ,



SQ-2 ,



SQ-3 ,



SQ-4 ,



SQ-5 ,



SQ-6 ,



SV-1 ,



SV-2 ,



SV-3 ,



SV-4 ,



SV-5 ,



SV-6

,



SV-7

,



SV-8

,



SV-9

,



SW-1

,



SW-2

,



SZ-1

,



SZ-2

,



SN-1

,



SN-2

,



SU-1,



SU-2,



SY-1,



SS-1,



SY-2,



SA-10,



SA-11,



SA-12,



SA-13,



SA-14,



SA-17

,



SA-18

, and



SA-20

.

21. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof of any one of the preceding claims, and a pharmaceutically acceptable excipient.

22. Use of an effective amount of a compound of any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament, for treating a CNS–related disorder in a subject in need thereof.

23. The use of claim 22, wherein the CNS–related disorder is a sleep disorder, an eating disorder, a mood disorder, a schizophrenia spectrum disorder, a convulsive disorder, a disorder of memory and/or cognition, a movement disorder, a personality disorder, autism spectrum disorder, pain, traumatic brain injury, a vascular disease, a substance abuse disorder and/or withdrawal syndrome, or tinnitus.

24. The use of claim 22, wherein the CNS-related disorder is depression (e.g., post-partum depression).

25. The use of claim 22, wherein the CNS-related disorder is tremor (e.g., essential tremor).

26. The use of claim 22, wherein the CNS-related disorder is an eating disorder (e.g., anorexia nervosa, bulimia nervosa, binge-eating disorder, cachexia).

27. The use of claim 21 wherein the compound is to be administered orally, subcutaneously, intravenously, or intramuscularly.

28. The use of claim 22 wherein the compound is to be administered chronically.

29. Use of an effective amount of a compound of the Formula (**I**) in the manufacture of a medicament, for inducing sedation and/or anesthesia.

30. Use of an effective amount of a compound of the Formula (**I**) in the manufacture of a medicament, for treating seizure.

31. Use of an effective amount of a compound of the Formula (**I**) in the manufacture of a medicament, for treating epilepsy.

32. Use of an effective amount of a compound of the Formula (**I**) in the manufacture of a medicament, for treating status epilepticus (SE).

33. The use of claim 32, wherein the status epilepticus is convulsive status epilepticus (*e.g.,* early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus) or non-convulsive status epilepticus, (*e.g.,* generalized status epilepticus, complex partial status epilepticus).

34. Use of a therapeutically effective amount of a compound, a pharmaceutically acceptable salt thereof, or pharmaceutical composition of one of a compound of Formula (**I**) in the manufacture of a medicament, for treating a disorder (e.g., a disorder as described herein, e.g., a disorder related to GABA function).